

SAPIENS INTERNATIONAL CORP N V  
Form SC 13D/A  
February 02, 2012

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

SCHEDULE 13D  
Under the Securities Exchange Act of 1934  
(Amendment No. 4)\*

Sapiens International Corporation N.V.

---

(Name of Issuer)

Common Shares, Par Value €0.01 Per Share

---

(Title of Class of Securities)

N7716A102

---

(CUSIP Number)

Amit Ben-Yehuda  
Kardan Technologies Ltd.  
154 Menachem Begin Street  
Tel Aviv 64921, Israel  
Tel: (972)(3) 608-3444  
Fax: (972)(3) 608-3434

Anat Treibatch  
Formula Vision Technologies (F.V.T.) Ltd.  
1 Hashikma Street  
Savyon 56530, Israel  
Tel: (972)(3) 734-3100  
Fax: (972)(3) 736-7770

with a copy to:

Tuvia J. Geffen, Adv.  
Naschitz, Brandes & Co.  
5 Tuval Street  
Tel-Aviv 67897, Israel  
Tel: (972)(3) 623-5000  
Fax: (972)(3) 623-5005

---

(Name, Address and Telephone Number of Person Authorized to  
Receive Notices and Communications)

January 26, 2012

---

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the

following box o .

Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See § 240.13d-7 for other parties to whom copies are to be sent.

---

\*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

---

CUSIP No. N7716A102

Page 3 of 14 Pages

NAME OF REPORTING PERSONS.

1  
Formula Vision Portfolio Holdings Limited Partnership

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)   
(b)

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4  
OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6  
Israel

		SOLE VOTING POWER
	7	N/A
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER
	8	753,625
		SOLE DISPOSITIVE POWER
	9	N/A
		SHARED DISPOSITIVE POWER
	10	753,625

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11  
753,625

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13  
1.90%\*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

PN

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 4 of 14 Pages

1 NAME OF REPORTING PERSONS.

1 Formula Vision Holdings Ltd.

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

- 2 (a)   
 (b)

3 SEC USE ONLY

4 SOURCE OF FUNDS (SEE INSTRUCTIONS)

4 OO

5 CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

6 CITIZENSHIP OR PLACE OF ORGANIZATION

6 Israel

		7	SOLE VOTING POWER
			N/A
			SHARED VOTING POWER
		8	753,625
			SOLE DISPOSITIVE POWER
		9	N/A
			SHARED DISPOSITIVE POWER
		10	753,625

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11 753,625

12 CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13 1.90%\*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

CO

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 5 of 14 Pages

NAME OF REPORTING PERSONS.

1

Kardan Technologies Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

- (a)
- (b)

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4

OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6

Israel

SOLE VOTING POWER

7

N/A

NUMBER OF SHARES

SHARED VOTING POWER

BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

8

5,409,793

SOLE DISPOSITIVE POWER

9

N/A

SHARED DISPOSITIVE POWER

10

5,409,793

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

5,409,793

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13

13.67%\*



TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

CO

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 6 of 14 Pages

NAME OF REPORTING PERSONS.

1  
Kardan Israel Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)   
(b)

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4  
OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6  
Israel

		SOLE VOTING POWER
	7	N/A
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER
	8	5,409,793
		SOLE DISPOSITIVE POWER
	9	N/A
		SHARED DISPOSITIVE POWER
	10	5,409,793

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11  
5,409,793

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13  
13.67%\*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

CO

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 7 of 14 Pages

NAME OF REPORTING PERSONS.

1

Kardan Yazamut (2011) Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

- (a)
- (b)

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4

OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6

Israel

SOLE VOTING POWER

7

N/A

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

SHARED VOTING POWER

8

5,409,793

SOLE DISPOSITIVE POWER

9

N/A

SHARED DISPOSITIVE POWER

10

5,409,793

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

5,409,793

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13

13.67%\*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

CO

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 8 of 14 Pages

NAME OF REPORTING PERSONS.

1

Formula Vision Technologies (F.V.T.) Ltd.

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2

- (a)
- (b)

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4

OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5

CITIZENSHIP OR PLACE OF ORGANIZATION

6

Israel

SOLE VOTING POWER

7

N/A

NUMBER OF  
SHARES  
BENEFICIALLY  
OWNED BY  
EACH  
REPORTING  
PERSON  
WITH

SHARED VOTING POWER

8

1,490,284

SOLE DISPOSITIVE POWER

9

N/A

SHARED DISPOSITIVE POWER

10

1,490,284

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11

1,490,284

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13

3.76%\*

TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

CO

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

CUSIP No. N7716A102

Page 9 of 14 Pages

NAME OF REPORTING PERSONS.

1  
Dan Goldstein

CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)

2 (a)   
(b)  x

SEC USE ONLY

3

SOURCE OF FUNDS (SEE INSTRUCTIONS)

4  
OO

CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(d) OR 2(e)

5  
 o

CITIZENSHIP OR PLACE OF ORGANIZATION

6  
Israel

		SOLE VOTING POWER
	7	N/A
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH		SHARED VOTING POWER
	8	1,490,284
		SOLE DISPOSITIVE POWER
	9	N/A
		SHARED DISPOSITIVE POWER
	10	1,490,284

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

11  
1,490,284

CHECK IF AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)

12  
 o

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13  
3.76%\*



TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

14

IN

\* The calculations are based on a total of 39,587,694 Common Shares outstanding.

---

The undersigned, Formula Vision Portfolio Holdings Limited Partnership ("Formula Vision LP"), Formula Vision Holdings Ltd. ("Formula Vision GP"), Kardan Technologies Ltd. ("Kardan Technologies"), Kardan Israel Ltd. ("Kardan Israel"), Kardan Yazamut (2011) Ltd. ("Kardan Yazamut"), Formula Vision Technologies (F.V.T.) Ltd. ("FVT") and Dan Goldstein (together, the "Reporting Persons") hereby file this Amendment No. 4 to Schedule 13D (the "Amendment"), which amends the Schedule 13D filed by the Reporting Persons on July 29, 2011, Amendment No. 1 to Schedule 13D filed by the Reporting Persons on August 25, 2011, Amendment No. 2 to Schedule 13D filed by the Reporting Persons on October 11, 2011 and Amendment No. 3 to Schedule 13D filed by the Reporting Persons on November 21, 2011, with respect to the Common Shares, par value €0.01 per share (the "Common Shares"), of Sapiens International Corporation N.V., a Curaçao company ("Sapiens"). The Amendment (i) amends and supplements Items 3, 4, 5 and 6 of the Schedule 13D, as amended, and (ii) adds Exhibit 14 under Item 7 of the Schedule 13D, as amended.

Item 3. Source and Amount of Funds or Other Consideration

On January 26, 2012, Formula Vision LP distributed to its limited partners, Kardan Technologies and FVT, 6,782,618 Common Shares beneficially owned by Formula Vision LP (the "Distribution"). 5,376,168 Common Shares were distributed by Formula Vision LP to Kardan Technologies and 1,406,450 Common Shares were distributed by Formula Vision LP to FVT.

Item 4. Purpose of Transaction

On January 26, 2012, Kardan Technologies, FVT and Formula Systems (1985) Ltd. ("Formula Systems") entered into a Share Purchase Agreement ("Purchase Agreement") pursuant to which (i) Kardan Technologies sold to Formula Systems 720,000 Common Shares for a purchase price of \$4.00 per Common Share, or an aggregate purchase price of \$2,880,000, and (ii) FVT sold to Formula Systems 880,000 Common Shares for a purchase price of \$4.00 per Common Share, or an aggregate purchase price of \$3,520,000. The foregoing summary of the Purchase Agreement is qualified in its entirety by reference to the full text of the Purchase Agreement included as Exhibit 14 hereto and is incorporated herein by reference.

In connection with the consummation of the transactions contemplated by the Purchase Agreement, Kardan Technologies agreed with Formula Systems that it shall cause the member of Sapiens' Board of Directors recommended by Kardan Technologies to resign from his office within two business days as of delivery to Kardan Technologies of such written request from Formula Systems, provided that such resignation shall be conditioned upon a representative of Kardan Technologies being simultaneously appointed as an observer to Sapiens' Board of Directors.

The information set forth in Items 3, 5 and 6 is incorporated herein by reference.

Each of the Reporting Persons intends to continuously review its investment in Sapiens, and may in the future determine, either alone or as part of a group (i) to acquire additional securities of Sapiens, through open market purchases, private agreements or otherwise, (ii) to dispose of all or a portion of the securities of Sapiens owned by it or (iii) to take any other available course of action, which could involve one or more of the types of transactions or have one or more of the results described in paragraphs (a) – (j) of Item 4 of Schedule 13D. Notwithstanding anything contained herein, each of the Reporting Persons specifically reserves the right to change its intention with respect to any or all of such matters. In reaching any decision as to its course of action (as well as to the specific elements thereof), each of the Reporting Persons currently expects that it would take into consideration a variety of factors, including, but not limited to, Sapiens's business and prospects, other developments concerning Sapiens and its businesses generally, other business opportunities available to the Reporting Persons, developments with respect to the business of the Reporting Persons, changes in law and government regulations, general economic conditions and

money and stock market conditions, including the market price of the securities of Sapiens.

Item 5.

Interest in Securities of the Issuer

(a) The calculations included herein are based on a total of 39,587,694 Common Shares outstanding.

Page 10 of 14 Pages

---

As of January 26, 2012, Formula Vision LP directly beneficially owns 753,625 Common Shares, representing approximately 1.90% of the outstanding Common Shares, all of which are held in escrow with an escrow agent until August 2012 to secure the indemnification and other obligations of Formula Vision LP to Sapiens. Formula Vision LP disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons.

As of January 26, 2012, Formula Vision GP does not directly beneficially own any Common Shares. Formula Vision GP is the general partner of Formula Vision LP. By reason of its ability to influence the control of Formula Vision LP, Formula Vision GP may be deemed to indirectly beneficially own, and share the power to vote and dispose of, the 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. Formula Vision GP disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 753,625 Common Shares directly beneficially owned by Formula Vision LP.

As of January 26, 2012, Kardan Technologies directly beneficially owns 4,656,168 Common Shares, representing approximately 11.76% of the outstanding Common Shares. Kardan Technologies is the limited partner of Formula Vision LP and owns 49% of the shares of Formula Vision GP. By reason of its ability to influence the control of Formula Vision LP and Formula Vision GP, Kardan Technologies may be deemed to indirectly beneficially own, and share the power to vote and dispose of, 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. Kardan Technologies disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 753,625 Common Shares it directly beneficially owns.

As of January 26, 2012, Kardan Israel does not directly beneficially own any Common Shares. Kardan Israel owns 84.94% of the shares of Kardan Technologies. By reason of its ability to influence the control of Kardan Technologies, Kardan Israel may be deemed to indirectly beneficially own, and share the power to vote and dispose of, (i) the 4,656,168 Common Shares directly beneficially owned by Kardan Technologies, representing approximately 11.76% of the outstanding Common Shares, and (ii) the 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. Kardan Israel disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 4,656,168 Common Shares directly beneficially owned by Kardan Technologies and the 753,625 Common Shares directly beneficially owned by Formula Vision LP.

As of January 26, 2012, Kardan Yazamut does not directly beneficially own any Common Shares. Kardan Yazamut owns 73.67% of the shares of Kardan Israel. By reason of its ability to influence the control of Kardan Israel, Kardan Yazamut may be deemed to indirectly beneficially own, and share the power to vote and dispose of, (i) the 4,656,168 Common Shares directly beneficially owned by Kardan Technologies, representing approximately 11.76% of the outstanding Common Shares, and (ii) the 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. Kardan Yazamut disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 4,656,168 Common Shares directly beneficially owned by Kardan Technologies and the 753,625 Common Shares directly beneficially owned by Formula Vision LP.

As of January 26, 2012, FVT directly beneficially owns 736,659 Common Shares, representing approximately 1.86% of the outstanding Common Shares. FVT is the limited partner of Formula Vision LP and owns 51% of the shares of Formula Vision GP. In addition, by reason of its ability to influence the control of Formula Vision LP and Formula Vision GP, FVT may be deemed to indirectly beneficially own, and share the power to vote and dispose of, 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. FVT disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 753,625 Common Shares directly beneficially owned by Formula Vision LP.

As of January 26, 2012, Dan Goldstein does not directly beneficially own any Common Shares. Mr. Goldstein owns 55.14% of the shares of FVT. By reason of his ability to influence the control of FVT, Mr. Goldstein may be deemed to indirectly beneficially own, and share the power to vote and dispose of, (i) the 736,659 Common Shares directly beneficially owned by FVT, representing approximately 1.86% of the outstanding Common Shares and (ii) the 753,625 Common Shares directly beneficially owned by Formula Vision LP, representing approximately 1.90% of the outstanding Common Shares. Mr. Goldstein disclaims beneficial ownership of the Common Shares owned by the other Reporting Persons other than the 736,659 Common Shares directly beneficially owned by FVT and the 753,625 Common Shares directly beneficially owned by Formula Vision LP.

(b) As of January 26, 2012, Formula Vision LP, Formula Vision GP, Kardan Technologies, Kardan Israel, Kardan Yazamut, FVT and Dan Goldstein share the power to vote and dispose of, 753,625 Common Shares directly beneficially owned by Formula Vision LP.

As of January 26, 2012, Kardan Technologies, Kardan Israel and Kardan Yazamut share the power to vote and dispose of, 4,656,168 Common Shares directly beneficially owned by Kardan Technologies.

As of January 26, 2012, FVT and Dan Goldstein share the power to vote and dispose of, 736,659 Common Shares directly beneficially owned by FVT.

(c) Except as previously described in Items 3 and 4 above, no transactions in the Common Shares have been effected by the Reporting Persons during the past 60 days.

(d) None

(e) As set forth in Items 3 and 4, as of January 26, 2012, each of Formula Vision LP, Formula Vision GP, FVT and Dan Goldstein ceased to be the beneficial owner of more than 5% of the issued and outstanding Common Shares.

Item 6. Contracts, Arrangements, Understandings or Relationships with Respect to Securities of the Issuer

The information set forth in Items 3, 4 and 5 is incorporated herein by reference.

Pursuant to the Purchase Agreement, (i) Kardan Technologies sold to Formula Systems 720,000 Common Shares for a purchase price of \$4.00 per Common Share, or an aggregate purchase price of \$2,880,000, and (ii) FVT sold to Formula Systems 880,000 Common Shares for a purchase price of \$4.00 per Common Share, or an aggregate purchase price of \$3,520,000. The foregoing summary of the Purchase Agreement is qualified in its entirety by reference to the full text of the Purchase Agreement included as Exhibit 14 hereto and is incorporated herein by reference.

Item 7. Material to be Filed as Exhibits

Exhibit 14 Share Purchase Agreement, dated as of January 26, 2012, by and among Formula Systems (1985) Ltd., Kardan Technologies Ltd. and Formula Vision Technologies (F.V.T.) Ltd. (incorporated herein by reference to Exhibit 99.1 to Amendment No. 19 to Schedule 13D of Formula Systems (1985) Ltd., filed on January 31, 2012).

Signatures

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 2, 2012

Formula Vision Portfolio Holdings Limited Partnership

By: Formula Vision Holdings Ltd., its general partner

By: /s/ Ronnen Yitzhak  
Name: Ronnen Yitzhak  
Title: Director

By: /s/ Amit Ben-Yehuda  
Name: Amit  
Ben-Yehuda  
Title: Director

Formula Vision Holdings Ltd.

By: /s/ Ronnen Yitzhak  
Name: Ronnen Yitzhak  
Title: Director

By: /s/ Amit Ben-Yehuda  
Name: Amit Ben-Yehuda  
Title: Director

Kardan Technologies Ltd.

By: /s/ Yosef Grunfeld  
Yosef Grunfeld  
Director

By: /s/ Amit Ben-Yehuda  
Name: Amit Ben-Yehuda  
Title: Chief Executive  
Officer

Kardan Israel Ltd.

By: /s/ Yosef Grunfeld  
Yosef Grunfeld  
Chairman of the Board

By: /s/ Asher Elmoznino  
Asher Elmoznino  
CFO

Kardan Yazamut (2011) Ltd.

By: /s/ Yosef Grunfeld  
Yosef Grunfeld  
Chairman of the Board

By: /s/ Asher Elmoznino  
Asher Elmoznino  
CFO

Formula Vision Technologies (F.V.T.) Ltd.

By: /s/ Ronnen Yitzhak  
Name: Ronnen Yitzhak  
Title: Director

By: /s/ Anat Treibatch  
Name: Anat Treibatch  
Title: CFO

/s/ Dan Goldstein  
Dan Goldstein